These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22170794)

  • 21. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial.
    Haukeland JW; Konopski Z; Eggesbø HB; von Volkmann HL; Raschpichler G; Bjøro K; Haaland T; Løberg EM; Birkeland K
    Scand J Gastroenterol; 2009; 44(7):853-60. PubMed ID: 19811343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum Fetuin-A levels in obese children with biopsy proven nonalcoholic fatty liver disease.
    Pampanini V; Inzaghi E; Germani D; Alterio A; Puglianiello A; Alisi A; Nobili V; Cianfarani S
    Nutr Metab Cardiovasc Dis; 2018 Jan; 28(1):71-76. PubMed ID: 29122442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of caloric restriction on fetuin-A and cardiovascular risk factors in rats and humans: a randomized controlled trial.
    Choi KM; Han KA; Ahn HJ; Lee SY; Hwang SY; Kim BH; Hong HC; Choi HY; Yang SJ; Yoo HJ; Baik SH; Choi DS; Min KW
    Clin Endocrinol (Oxf); 2013 Sep; 79(3):356-63. PubMed ID: 23067229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I.
    Arturi F; Succurro E; Procopio C; Pedace E; Mannino GC; Lugarà M; Procopio T; Andreozzi F; Sciacqua A; Hribal ML; Perticone F; Sesti G
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1640-4. PubMed ID: 21816784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans.
    Peter A; Kovarova M; Staiger H; Machann J; Schick F; Königsrainer A; Königsrainer I; Schleicher E; Fritsche A; Häring HU; Stefan N
    Am J Physiol Endocrinol Metab; 2018 Mar; 314(3):E266-E273. PubMed ID: 29138227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease.
    Croci I; Byrne NM; Choquette S; Hills AP; Chachay VS; Clouston AD; O'Moore-Sullivan TM; Macdonald GA; Prins JB; Hickman IJ
    Gut; 2013 Nov; 62(11):1625-33. PubMed ID: 23077135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Higher fetuin-A level is associated with coexistence of elevated alanine aminotransferase and the metabolic syndrome in the general population.
    Koch M; Jacobs G; Hampe J; Rosenstiel P; Krawczak M; Nöthlings U
    Metab Syndr Relat Disord; 2013 Dec; 11(6):377-84. PubMed ID: 23971757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating levels of fetuin-A are associated with moderate-severe hepatic steatosis in young adults.
    Filardi T; Panimolle F; Tiberti C; Crescioli C; Lenzi A; Pallotta N; Morano S
    J Endocrinol Invest; 2021 Jan; 44(1):105-110. PubMed ID: 32350824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
    Bugianesi E; Gentilcore E; Manini R; Natale S; Vanni E; Villanova N; David E; Rizzetto M; Marchesini G
    Am J Gastroenterol; 2005 May; 100(5):1082-90. PubMed ID: 15842582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum fetuin B level increased in subjects of nonalcoholic fatty liver disease: a case-control study.
    Zhu J; Wan X; Wang Y; Zhu K; Li C; Yu C; Li Y
    Endocrine; 2017 Apr; 56(1):208-211. PubMed ID: 27628583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melatonin improves insulin resistance and hepatic steatosis through attenuation of alpha-2-HS-glycoprotein.
    Heo JI; Yoon DW; Yu JH; Kim NH; Yoo HJ; Seo JA; Kim SG; Choi KM; Baik SH; Choi DS; Kim NH
    J Pineal Res; 2018 Sep; 65(2):e12493. PubMed ID: 29607540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fetuin-A in newly detected type 2 diabetes mellitus as a marker of non-alcoholic fatty liver disease.
    Yamasandhi PG; Dharmalingam M; Balekuduru A
    Indian J Gastroenterol; 2021 Dec; 40(6):556-562. PubMed ID: 34950996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity.
    Bugianesi E; Pagotto U; Manini R; Vanni E; Gastaldelli A; de Iasio R; Gentilcore E; Natale S; Cassader M; Rizzetto M; Pasquali R; Marchesini G
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3498-504. PubMed ID: 15797948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum fetuin-A concentration predicts glycaemic outcomes in people with prediabetes: a prospective study from eastern India.
    Dutta D; Mondal SA; Kumar M; Hasanoor Reza AH; Biswas D; Singh P; Chakrabarti S; Mukhopadhyay S
    Diabet Med; 2014 Dec; 31(12):1594-9. PubMed ID: 24975463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does metformin treatment influence bone formation in patients with nonalcoholic fatty liver disease?
    Soifer E; Gavish D; Shargorodsky M
    Horm Metab Res; 2015 Jul; 47(8):556-9. PubMed ID: 25671801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
    Forcheron F; Abdallah P; Basset A; del Carmine P; Haffar G; Beylot M
    Obesity (Silver Spring); 2009 Jul; 17(7):1381-9. PubMed ID: 19553925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels.
    Stefanovic-Racic M; Perdomo G; Mantell BS; Sipula IJ; Brown NF; O'Doherty RM
    Am J Physiol Endocrinol Metab; 2008 May; 294(5):E969-77. PubMed ID: 18349115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endoplasmic reticulum stress involved in the course of lipogenesis in fatty acids-induced hepatic steatosis.
    Liu J; Jin X; Yu CH; Chen SH; Li WP; Li YM
    J Gastroenterol Hepatol; 2010 Mar; 25(3):613-8. PubMed ID: 19929925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.